FDA-approved BRAF inhibitors

Encorafenib with binimetinib is approved by the FDA for treatment of metastatic non-small cell lung cancer with a BRAF V600E mutation

The Food and Drug Administration (FDA) approved Encorafenib (Braftovi, Array BioPharma Inc., a wholly owned subsidiary of Pfizer) and binimetinib (Mektovi, Array BioPharma Inc.) in November 2023 as m...
fda-approved-braf-inhibitors

Scan the code

Tag: FDA-approved BRAF inhibitors

Home / FDA-approved BRAF inhibitors

Categories

Encorafenib with binimetinib is approved by the FDA for treatment of metastatic non-small cell lung cancer with a BRAF V600E mutation

Information

Treatment

China (Beijing)

Romania

India (Hyderabad)

Cambodia

China (Shanghai)

Hong Kong